AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:AVNR
CUSIP05348P40
Phone+1-949-3896700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions
What is Avanir Pharmaceuticals' stock symbol?
Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."
What is the consensus analysts' recommendation for Avanir Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanir Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Avanir Pharmaceuticals been receiving favorable news coverage?
Media stories about AVNR stock have been trending positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Avanir Pharmaceuticals earned a news sentiment score of 0.39 on Accern's scale. They also gave media stories about the healthcare company an impact score of 47.31 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Avanir Pharmaceuticals?
Shares of AVNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Avanir Pharmaceuticals?
Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.
MarketBeat Community Rating for Avanir Pharmaceuticals (NASDAQ AVNR)
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.
